3D Systems Corporation (NYSE: DDD) saw its stock soar 5.19% in the pre-market trading session on Wednesday, driven by positive news surrounding its subsidiary, Systemic Bio.
Systemic Bio, a wholly-owned company of 3D Systems focused on accelerating drug discovery and development, has been named the winner of the prestigious SLAS 2025 Innovation Award. This award recognizes groundbreaking technological advancements poised to drive innovation in laboratory science and automation.
The award highlights Systemic Bio's proprietary h-VIOS™ platform, designed to accelerate drug discovery and development using bioprinted human tissues. The platform enables early identification of safety concerns, capturing risks that historically have only been discovered during clinical trials, even after non-human primate studies failed to flag such issues.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.